Compare PPIH & NVNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PPIH | NVNO |
|---|---|---|
| Founded | 1993 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Pollution Control Equipment | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 189.6M | 16.7M |
| IPO Year | N/A | N/A |
| Metric | PPIH | NVNO |
|---|---|---|
| Price | $33.00 | $0.36 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 92.6K | ★ 440.2K |
| Earning Date | 12-12-2025 | 10-31-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.71 | N/A |
| Revenue | ★ $200,783,000.00 | N/A |
| Revenue This Year | $25.58 | N/A |
| Revenue Next Year | $15.38 | N/A |
| P/E Ratio | $19.27 | ★ N/A |
| Revenue Growth | ★ 30.74 | N/A |
| 52 Week Low | $8.81 | $0.30 |
| 52 Week High | $36.48 | $5.62 |
| Indicator | PPIH | NVNO |
|---|---|---|
| Relative Strength Index (RSI) | 72.96 | 42.75 |
| Support Level | $31.81 | $0.32 |
| Resistance Level | $33.64 | $0.37 |
| Average True Range (ATR) | 1.74 | 0.04 |
| MACD | 0.22 | 0.02 |
| Stochastic Oscillator | 65.59 | 64.83 |
Perma-Pipe International Holdings Inc is engaged in the manufacture and sale of products in the reportable segment of Piping Systems. The company engineers, designs, manufactures, and sells specialty piping systems and leak detection systems. Specialty piping systems include insulated and jacketed district heating and cooling piping systems for efficient energy distribution from central energy plants to multiple locations, primary and secondary containment piping systems for transporting chemicals, hazardous fluids, and petroleum products, and the coating and insulation of oil and gas gathering and transmission pipelines. It operates in the United States, Canada, the Middle East, Europe, India, and other countries.
enVVeno Medical Corp is a late clinical-stage medical device company focused on advancing bioprosthetic (tissue-based) solutions to improve the standard of care for treating venous disease. The company's product, VenoValve, is a surgical replacement venous valve that is currently being evaluated in a U.S. pivotal study. The company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the products are designed to act as one-way valves to help assist in propelling blood up the veins of the leg, and back to the heart and lungs. The company has determined that it currently operates in a single segment, Medical Device development, located in a single geographic location, the United States.